India Pharma Outlook Team | Friday, 19 September 2025
Sai Life Sciences, a contract research, development, and manufacturing organization (CRDMO) focused on innovative medicines, announced Unit VI inauguration in Bidar, India, to manufacture veterinary active pharmaceutical ingredients (APIs). The new facility is adjacent to Unit IV, Sai Life Sciences’ core-site for API manufacturing.
Unit VI has been designed to comply with best practices for safety, sustainability and regulatory compliance, producing high-quality APIs for veterinary use. This expansion enables Sai Life Sciences to support many global leaders in animal health with scaling, sustainable and efficient manufacturing capabilities.
Also Read: How Advanced Training Methods can Enhance Patient Care
Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said: “This investment strengthens our ability to meet the growing global demand for high-quality veterinary pharmaceuticals while ensuring the highest standards of innovation, efficiency, and sustainability. We are proud to support our innovator partners in their mission of offering reliable solutions that enhance animal well-being.”
The veterinary API market represents a real growth opportunity due to increased demand for veterinary pharmaceutical products and advances in veterinary medicine. Investment of Sai Life Sciences into the facility is consistent with its stated approach to build its position in niche, higher-value segments of the pharmaceutical industry.
Sai Life Sciences has recorded over 20 years of experience manufacturing APIs, and is a recognized partner in API supply, being lauded for its advanced process capability, operational execution, and quality assurance. The new facility is utilizing advanced technologies, solid supply chain functionality, and leading safety culture to be a consistent and price-competitive source of animal health APIs.
